Boehringer Ingelheim and Medivir sign agreement for novel HIV/AIDS antiviral
MIV-310, as a possible treatment for multi-drug resistant patients
17-Jul-2003 -
Boehringer Ingelheim and Medivir today announced that Medivir has out-licensed its innovative HIV antiviral MIV-310 to Boehringer Ingelheim.
MIV-310 is an extremely potent inhibitor of reverse transcriptase and belongs to the nucleoside analogue class (NRTI). Currently, it is in phase II ...
AIDS
Boehringer Ingelheim
Denmark
+8